

In the claims:

- 1.-6. (canceled)
7. (Currently amended) A drug comprising a 2-imidazolyl disulfide and an acceptable carrier for intravenous administration, said 2-imidazolyl disulfide being useful in reducing or eliminating thioredoxin-associated apoptosis inhibition~~and~~.
8. (Currently amended) A drug comprising a 2-imidazolyl disulfide and an acceptable carrier, for intravenous administration said 2-imidazolyl disulfide being useful in inhibiting thioredoxin stimulated cell growth~~and~~.
9. (Previously presented) The drug of claim 7, wherein said 2-imidazolyl disulfide is 1-methylpropyl 2-imidazolyl disulfide.
10. (Previously presented) The drug of claim 8, wherein said 2-imidazolyl disulfide is 1-methylpropyl 2-imidazolyl disulfide.
11. (Previously presented) The drug of claim 7, wherein said 2-imidazolyl disulfide inhibits tumor growth.
12. (Previously presented) The drug of claim 8, wherein said 2-imidazolyl disulfide inhibits tumor growth.
13. (Previously presented) The drug of claim 7, wherein said 2-imidazolyl disulfide inhibits thioredoxin.
14. (Previously presented) The drug of claim 8, wherein said 2-imidazolyl disulfide inhibits thioredoxin.
15. (Previously presented) The drug of claim 7, wherein said 2-imidazolyl disulfide irreversibly binds to thioredoxin.
16. (Previously presented) The drug of claim 8, wherein said 2-imidazolyl disulfide irreversibly binds to thioredoxin.

17. (Previously presented) The drug of claim 7, wherein said 2-imidazolyl disulfide irreversibly binds to Cys⁷³ of thioredoxin.
18. (Previously presented) The drug of claim 8, wherein said 2-imidazolyl disulfide irreversibly binds to Cys⁷³ of thioredoxin.
19. (New) A drug comprising a 2-imidazolyl disulfide and an acceptable carrier for oral administration, said 2-imidazolyl disulfide being useful in reducing or eliminating thioredoxin-associated apoptosis inhibition.
20. (New) A drug comprising a 2-imidazolyl disulfide and an acceptable carrier, for oral administration said 2-imidazolyl disulfide being useful in inhibiting thioredoxin stimulated cell growth.
21. (Previously presented) The drug of claim 19, wherein said 2-imidazolyl disulfide is 1-methylpropyl 2-imidazolyl disulfide.
22. (New) The drug of claim 20, wherein said 2-imidazolyl disulfide is 1-methylpropyl 2-imidazolyl disulfide.
23. (New) The drug of claim 19, wherein said 2-imidazolyl disulfide inhibits tumor growth.
24. (New) The drug of claim 20, wherein said 2-imidazolyl disulfide inhibits tumor growth.
25. (New) The drug of claim 19, wherein said 2-imidazolyl disulfide inhibits thioredoxin.
26. (New) The drug of claim 20, wherein said 2-imidazolyl disulfide inhibits thioredoxin.
27. (New) The drug of claim 19, wherein said 2-imidazolyl disulfide irreversibly binds to thioredoxin.
28. (New) The drug of claim 20, wherein said 2-imidazolyl disulfide irreversibly binds to thioredoxin.

29. (New) The drug of claim 19, wherein said 2-imidazolyl disulfide irreversibly binds to Cys⁷³ of thioredoxin.
30. (New) The drug of claim 20, wherein said 2-imidazolyl disulfide irreversibly binds to Cys⁷³ of thioredoxin.